Introduction: Infliximab is a chimeric anti-tumor necrosis alpha (TNF-α) monoclonal antibody that induces inflammatory cell lysis. Sarcoidosis-like reaction in patients treated with anti-TNF-α agents is uncommon
Background Tumour necrosis factor α (TNF-α) is pivotal in sarcoid granuloma formation, and inhibitor...
Sarcoidosis is an inflammatory, granulomatous disease of unknown etiology that most commonly afflict...
International audienceAnti-TNF-alpha agents have been tried in cases of refractory sarcoidosis, givi...
AbstractSarcoidosis is a multisystem granulomatous inflammatory disease of unknown etiology. There i...
Objectives: to report 2 cases of sarcoidosis developed during treatment with anti-TNFalfa antagonist...
Abstract Infliximab is a chimeric monoclonal antibody against tumour necrosis factor (TNF)‐α, with a...
Introduction. Sarcoidosis is a multisystemic granulomatous disorder characterized by multiple noncas...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Since the introduction of anti-tumour necrosis factor [TNF] therapy in inflammatory diseases, parado...
Sarcoidosis is a systemic chronic granulomatous disease of unknown etiology. It predominantly involv...
Drug-induced sarcoidosis-like disease is a rare side effect of anti-tumor necrosis factor (anti-TNF)...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new ‘‘class effect’ ’ para-...
AbstractIn severe cases of sarcoidosis treatment can be very difficult. The common treatment strateg...
Biological agents which specifically block tumor necrosis factor (TNF) have been reported as useful ...
Background Tumour necrosis factor α (TNF-α) is pivotal in sarcoid granuloma formation, and inhibitor...
Sarcoidosis is an inflammatory, granulomatous disease of unknown etiology that most commonly afflict...
International audienceAnti-TNF-alpha agents have been tried in cases of refractory sarcoidosis, givi...
AbstractSarcoidosis is a multisystem granulomatous inflammatory disease of unknown etiology. There i...
Objectives: to report 2 cases of sarcoidosis developed during treatment with anti-TNFalfa antagonist...
Abstract Infliximab is a chimeric monoclonal antibody against tumour necrosis factor (TNF)‐α, with a...
Introduction. Sarcoidosis is a multisystemic granulomatous disorder characterized by multiple noncas...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Since the introduction of anti-tumour necrosis factor [TNF] therapy in inflammatory diseases, parado...
Sarcoidosis is a systemic chronic granulomatous disease of unknown etiology. It predominantly involv...
Drug-induced sarcoidosis-like disease is a rare side effect of anti-tumor necrosis factor (anti-TNF)...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new ‘‘class effect’ ’ para-...
AbstractIn severe cases of sarcoidosis treatment can be very difficult. The common treatment strateg...
Biological agents which specifically block tumor necrosis factor (TNF) have been reported as useful ...
Background Tumour necrosis factor α (TNF-α) is pivotal in sarcoid granuloma formation, and inhibitor...
Sarcoidosis is an inflammatory, granulomatous disease of unknown etiology that most commonly afflict...
International audienceAnti-TNF-alpha agents have been tried in cases of refractory sarcoidosis, givi...
DOI
Add to ORKG